Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes

Nanoparticles that reshape the tumor milieu create a therapeutic window for effective T cell therapy in solid malignancies

(2018) Fan Zhang et al.   CANCER RESEARCH

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma

(2017) Chunyan Hao et al.   MEDICINE

Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)

(2017) Michael J. Wagner et al.   MOLECULAR CANCER THERAPEUTICS

Elimination of large tumors in mice by mRNA-encoded bispecific antibodies

(2017) Christiane R Stadler et al.   NATURE MEDICINE

Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy

(2016) Matthias A. Oberli et al.   NANO LETTERS

Translating nanoparticulate-personalized cancer vaccines into clinical applications: case study with RNA-lipoplexes for the treatment of melanoma

(2016) Stephan Grabbe et al.   Nanomedicine

Immunotherapy: Cancer vaccine triggers antiviral-type defences

(2016) Jolanda De Vries et al.   NATURE

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

(2016) Lena M. Kranz et al.   NATURE

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

(2016) Alena Gros et al.   NATURE MEDICINE

Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer

(2016) Michail Ignatiadis et al.   PLoS One

Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon

(2016) Katrijn Broos et al.   Molecular Therapy-Nucleic Acids

Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles

(2016) Elias J. Sayour et al.   OncoImmunology

Lipid-Based Nanocarriers for RNA Delivery

(2015) Hui Xue et al.   CURRENT PHARMACEUTICAL DESIGN

Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics

(2015) Cornelia Lorenzer et al.   JOURNAL OF CONTROLLED RELEASE

Dendritic-cell vaccines on the move

(2015) Rachel Lubong Sabado et al.   NATURE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Advances and Challenges of Liposome Assisted Drug Delivery

(2015) Lisa Sercombe et al.   Frontiers in Pharmacology

A randomized controlled phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC)

(2014) A. Awada et al.   ANNALS OF ONCOLOGY

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

(2014) Alena Gros et al.   JOURNAL OF CLINICAL INVESTIGATION

First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors

(2014) Beate Schultheis et al.   JOURNAL OF CLINICAL ONCOLOGY

Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine

(2014) Hui Yi Xue et al.   Nanomedicine

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer

(2013) Sebastian Strieth et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Exploiting the curative potential of adoptive T-cell therapy for cancer

(2013) Christian S. Hinrichs et al.   IMMUNOLOGICAL REVIEWS

PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells

(2013) Erin E. West et al.   JOURNAL OF CLINICAL INVESTIGATION

Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER)

(2013) Eun-Ae Cho et al.   LANCET

Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

(2012) Nadeem A. Sheikh et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Blockade of Myeloid-Derived Suppressor Cells after Induction of Lymphopenia Improves Adoptive T Cell Therapy in a Murine Model of Melanoma

(2012) K. N. Kodumudi et al.   JOURNAL OF IMMUNOLOGY

Developing mRNA-vaccine technologies

(2012) Thomas Schlake et al.   RNA Biology

Raising the Bar: The Curative Potential of Human Cancer Immunotherapy

(2012) S. A. Rosenberg   Science Translational Medicine

RNA-based vaccines

(2012) Jeffrey B. Ulmer et al.   VACCINE

Two years of Provenge

(2012) Eva M. Riedmann   Human Vaccines & Immunotherapeutics

Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis

(2011) U. Fasol et al.   ANNALS OF ONCOLOGY

Increased Frequency of CD4+CD25highFoxP3+ Regulatory T Cells in Patients with Hepatocellular Carcinoma

(2011) Xi Feng et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Novel Strategies to Improve DNA Vaccine Immunogenicity

(2011) Cevayir Coban et al.   CURRENT GENE THERAPY

Adjuvants for Enhancing the Immunogenicity of Whole Tumor Cell Vaccines

(2011) Cheryl Lai-Lai Chiang et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Transfection Efficiency of Cationic Lipids with Different Hydrophobic Domains in Gene Delivery

(2010) DeFu Zhi et al.   BIOCONJUGATE CHEMISTRY

The systemic toxicity of positively charged lipid nanoparticles and the role of Toll-like receptor 4 in immune activation

(2010) Ranit Kedmi et al.   BIOMATERIALS

Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity

(2010) S. Kreiter et al.   CANCER RESEARCH

Intracellular Toll-like Receptors

(2010) Amanda L. Blasius et al.   IMMUNITY

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

(2010) John H. Sampson et al.   JOURNAL OF CLINICAL ONCOLOGY

Liver antigen-presenting cells

(2010) Ian Nicholas Crispe   JOURNAL OF HEPATOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Liver as a Lymphoid Organ

(2009) Ian Nicholas Crispe   Annual Review of Immunology

Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: Key regulators of innate immunity

(2009) Paola M. Barral et al.   PHARMACOLOGY & THERAPEUTICS

MDA5/RIG-I and virus recognition

(2008) Osamu Takeuchi et al.   CURRENT OPINION IN IMMUNOLOGY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results

(2008) John T. Schiller et al.   VACCINE